Indeed, ADAM12 has been previously implicated in HB-EGF shedding44, 45, 47, and ADAM12 represents a compelling drug target through clinical association with diseases including hypertension, asthma, liver fibrosis, obesity, adverse pregnancy outcome, along with multiple cancers48. This evidence concerns the gene HBEGF and obesity due to melanocortin 4 receptor deficiency.